236 related articles for article (PubMed ID: 25736530)
41. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
Gu KW; Kim CK; Choi CH; Yoon YC; Park W
Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
[TBL] [Abstract][Full Text] [Related]
42. Concurrent Cisplatin-Based Chemoradiation in Squamous Cell Carcinoma of Cervix.
Hashmi H; Maqbool A; Ahmed S; Ahmed A; Sheikh K; Ahmed A
J Coll Physicians Surg Pak; 2016 Apr; 26(4):302-5. PubMed ID: 27097702
[TBL] [Abstract][Full Text] [Related]
43. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution.
Kinjyo Y; Nagai Y; Toita T; Kudaka W; Ariga T; Shimoji Y; Nakasone T; Taira Y; Arakaki Y; Nakamoto T; Wakayama A; Ooyama T; Maemoto H; Heianna J; Aoki Y
Br J Radiol; 2017 Aug; 90(1076):20170241. PubMed ID: 28707541
[TBL] [Abstract][Full Text] [Related]
44. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy.
Ittiamornlert P; Ruengkhachorn I
BMC Cancer; 2019 Jan; 19(1):51. PubMed ID: 30630439
[TBL] [Abstract][Full Text] [Related]
45. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Kurashige J; Hiyoshi Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Surg Today; 2016 Apr; 46(4):405-13. PubMed ID: 26036223
[TBL] [Abstract][Full Text] [Related]
46. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
[TBL] [Abstract][Full Text] [Related]
47. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
Jin J; Yang L; Liu D; Li W
BMJ Open; 2020 Jun; 10(6):e035031. PubMed ID: 32499266
[TBL] [Abstract][Full Text] [Related]
48. Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer.
Kawase S; Okuda T; Ikeda M; Ishihara S; Itoh Y; Yanagawa S; Ishigaki T
Gynecol Oncol; 2006 Sep; 102(3):493-9. PubMed ID: 16478629
[TBL] [Abstract][Full Text] [Related]
49. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.
Nagai Y; Toita T; Wakayama A; Nakamoto T; Ooyama T; Tokura A; Inamine M; Kudaka W; Murayama S; Aoki Y
Anticancer Res; 2012 Apr; 32(4):1475-9. PubMed ID: 22493388
[TBL] [Abstract][Full Text] [Related]
50. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
51. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
52. Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).
Sakata K; Sakurai H; Suzuki Y; Katoh S; Ohno T; Toita T; Kataoka M; Tanaka E; Kaneyasu Y; Uno T; Harima Y; Nakano T;
Acta Oncol; 2008; 47(3):434-41. PubMed ID: 18348003
[TBL] [Abstract][Full Text] [Related]
53. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
[TBL] [Abstract][Full Text] [Related]
54. External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation.
Schernberg A; Huguet F; Moureau-Zabotto L; Chargari C; Rivin Del Campo E; Schlienger M; Escande A; Touboul E; Deutsch E
Radiother Oncol; 2017 Jul; 124(1):110-117. PubMed ID: 28662871
[TBL] [Abstract][Full Text] [Related]
55. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy.
Micke O; Bruns F; Schäfer U; Prott FJ; Willich N
Anticancer Res; 2005; 25(3A):1663-6. PubMed ID: 16033078
[TBL] [Abstract][Full Text] [Related]
56. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
57. Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer.
Takeshita S; Kita T; Motoike Y; Umezawa K; Sugisaki S; Matsumoto S; Matsumoto Y; Ryo E; Ayabe T
J Obstet Gynaecol Res; 2010 Oct; 36(5):1009-14. PubMed ID: 20722988
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review.
Wu J; Chen M; Liang C; Su W
Oncotarget; 2017 Feb; 8(8):13400-13412. PubMed ID: 28077792
[TBL] [Abstract][Full Text] [Related]
59. Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from India.
Saibishkumar EP; Patel FD; Sharma SC
Bull Cancer; 2005 Jan; 92(1):E7-12. PubMed ID: 15811845
[TBL] [Abstract][Full Text] [Related]
60. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
